Alpha Emitter Market

The global Alpha Emitter Market is valued at USD 671.2 Million in 2023 and is projected to reach a value of USD 1751.5 Million by 2032 at a CAGR (Compound Annual Growth Rate) of 11.25% between 2024 and 2032.

Key highlights of Alpha Emitter Market

• In 2023, North America exhibited its market prowess, achieving the highest revenue share of 43.6%
• The Europe region is poised for remarkable growth, displaying a market share of 29.3% in 2023
• Radium (Ra-223) segment dominates the market with 54.5% of market share in 2023
• The Prostate Cancer segment will continue to assert its dominance by type, capturing the largest market share of 34.4% in 2023
• Natural Sources accounts for largest market share of 53.5% in 2023
• Additionally, the increasing investment in the research and development of alpha-emitting radiopharmaceuticals and subsequent regulatory approvals are key drivers of market growth

Alpha Emitter Market: Regional Overview

North America Dominated Sales with a 43.6% share in 2023. The robust market position in North America may be attributed to several factors together with the presence of a well-developed healthcare system, ongoing research and development efforts, and increasingly more cancer cases, which creates a demand for progressive treatment alternatives. moreover, partnerships between pharmaceutical agencies and studies establishments within the area contribute to the overall boom of the market. Although North America dominates the market, other regions are also witnessing a rising adoption of alpha emitters, indicating a global interest in these technologies for various medical and industrial purposes.

U.S. Alpha Emitter Market Overview

The U.S. Alpha Emitter market, valued at USD 204.5 Million in 2023 to USD 474.28 Million in 2032 is anticipated to grow at a CAGR of 9.8% from 2024 to 2032. The market for Alpha Emitter in the United States is continuously growing and evolving due to technological advancements. The country has a strong healthcare system, dedicated research and development efforts, and a high incidence of cancer, making it a significant contributor to the global Alpha Emitter market. For instance, according to the American Cancer Society's projections for 2024 in the United States, there will be an estimated 299,010 new cases of prostate cancer and approximately 35,250 deaths resulting from the disease. Market expansion is further fueled by regulatory approvals and strategic collaborations. The U.S. is at the forefront of advancements in the Alpha Emitter market, particularly in personalized medicine and targeted alpha therapy for cancer treatment. This influences both clinical applications and industrial uses, making the U.S. a crucial region in this market.

The global Alpha Emitter market can be categorized as Radionuclide, Source, Application and Region.

Alpha Emitter Market: Radionuclide Overview

In 2023, the Radium (Ra-223) segment dominated the market with 54.5% market share. The {Keyword}} market, segmented by radionuclide, includes Radium (Ra-223), Actinium (Ac-225), Lead (Pb-212), Astatine-211, Bismuth-213, Others. Radium-223 has gained significant market recognition and acceptance, particularly in the field of oncology for targeted alpha-particle radiotherapy. Its effectiveness in treating bone metastases has made it a preferred option in medical applications. For instance, In August 2022, the Radiation journal published an article discussing a study conducted by a researcher from Kindai University in Japan. The study aimed to determine the best method for utilizing Radium-223 therapy for patients with Metastatic Castration-Resistant Prostate Cancer. The research findings demonstrated that early administration of Ra-223 led to a notable enhancement in overall survival (OS). These results indicate that there could be advantages in administering Ra-223 before introducing new hormonal or anticancer agents.

Alpha Emitter Market: Application Overview

In 2023, the Prostate Cancer segment accounted for over 34.4% market share. Application segment is divided into Prostate Cancer, Bone Metastases, Ovarian, Cancer, Pancreatic Cancer, Endocrine Tumors, Others. This emphasizes the importance of alpha emitters in targeted therapies specifically designed for prostate cancer. The increasing prevalence of prostate cancer and a growing understanding of the benefits of targeted alpha therapy have driven the adoption of alpha emitters in this field. For instance, during their lifetime, approximately 1 out of every 8 men will receive a prostate cancer diagnosis. However, the risk of developing this cancer can differ among individuals due to factors such as age, race/ethnicity, and other variables. As research and clinical applications continue to advance, it is expected that the application landscape of the alpha emitter market will undergo further diversification and innovation. For instance, In April 2023, a publication on NCBI reported that researchers from Wake Forest University Health Sciences and the University of Iowa discovered that radium-223 dichloride, a radiopharmaceutical that emits alpha-particles, improves the overall survival of prostate cancer patients with bone metastases.

Alpha Emitter Market: Source Overview

In 2023, the Natural Sources segment accounted for over 53.5% market share. Source segment is divided into Natural Sources and Artificially produced sources. Natural sources can be attributed to factors like cost-effectiveness, environmental concerns, and the inherent reliability associated with utilizing alpha emitters from natural sources. The substantial market share held by the Natural Sources segment emphasizes the industry's inclination towards sustainable and readily available resources, which sets the stage for future advancements and investments in alpha emitter technologies.

Key Trends

• Research and development have continuously aimed at advancing and broadening the uses of targeted alpha therapy. Notably, there was a huge awareness on improving and expanding the layout of radiopharmaceuticals that emit alpha particles.
• Alpha emitters like americium-241 are being more widely used in various industries for purposes such as detecting flaws in materials during manufacturing and construction, in a method known as non-destructive testing. They are also helpful in smoke detection systems, improving fire safety measures in industrial settings. This shows that alpha emitters have a wider range of uses beyond their traditional role in medicine.
• The utilization of alpha-emitting radiopharmaceuticals alongside diagnostic imaging modalities has become a prevailing trend in imaging technologies. This advancement enables enhanced visualization and monitoring of treatment results.
• The field of oncology is experiencing a movement towards personalized and precision medicine, wherein the use of alpha emitters is becoming significant. The importance of customizing treatments according to the unique attributes of each patient and the specific characteristics of their tumor is growing.

Premium Insights

The sustained growth of the Alpha Emitter market is driven by various factors. One of the key drivers is the increasing prevalence of cancer worldwide, which has led to a growing demand for effective and targeted therapies. For instance, According to American Cancer Society's projections for 2023, 1.9 million new cancer cases are expected to be diagnosed in the US in 2023. Alpha emitters, with their unique ability to deliver precise and localized radiation, are highly valued in treating cancer. Furthermore, healthcare professionals and patients are increasingly aware of the potential benefits of targeted alpha therapy, which further contributes to market expansion.

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Surge in cancer cases propels market due to the burgeoning global occurrence of cancer cases

The increasing prevalence of cancer worldwide, driven by factors like aging populations and lifestyle changes, is leading to a greater need for advanced and successful cancer treatments. For instance, by 2040, it is estimated by the International Agency for Research on Cancer (IARC) that there will be a significant rise in cancer cases and related deaths worldwide, reaching 27.5 million new cases and 16.3 million fatalities. This growth is primarily attributed to population growth and aging. Furthermore, around 70% of cancer deaths occur in low- and middle-income nations. As a result, the increasing occurrence of cancer and cardiovascular diseases is anticipated to create a higher need for alpha emitters, which are used in the treatment of these medical conditions. Alpha emitters, which use a targeted approach in cancer therapy, are being increasingly acknowledged as valuable tools in combating the growing burden of malignancies.

The inherent challenge of a short half-life in alpha-emitting radiopharmaceuticals poses logistical hurdles, impacting production, distribution, and utilization

The need for timely delivery to medical facilities poses logistical challenges, impacting the overall efficiency of treatment protocols. Overcoming this restraint requires advancements in production processes, including faster synthesis methods and streamlined supply chain logistics, to ensure the timely availability of alpha emitters for medical applications.

Growing recognition of advantages in targeted alpha therapy due to the expanding awareness among healthcare professionals, patients, and the public regarding the efficacy of targeted alpha therapy

As research continues to demonstrate the precision and effectiveness of alpha emitters in treating specific cancers, there is an increasing willingness to explore TAT therapies. Educational initiatives, awareness campaigns, and collaborations between healthcare providers and industry stakeholders can further enhance understanding and acceptance, driving the adoption of alpha emitters in clinical settings.

Competitive Landscape

The Alpha Emitter market is highly competitive, with multiple key players vying for dominance through strategic initiatives and product innovations. Prominent companies, including Actinium Pharmaceuticals, Inc., Bayer AG, and Alpha Tau Medical Ltd., are actively involved in research and development to improve their alpha emitter offerings, particularly in the fields of oncology and industry. Partnerships, collaborations, and mergers are commonly used strategies to solidify their positions in the market. Furthermore, new players are entering the arena with innovative technologies and therapies, intensifying the competition. The market is influenced by technological advancements, regulatory approvals, and a focus on meeting unmet medical needs.

The key players in the global Alpha Emitter market include - Actinium Pharmaceutical Inc., Alpha Tau Medical Ltd, Bayer AG, Bracco, Cardinal Health, Eckert & Ziegle, Fusion Pharmaceuticals, IBA Worldwide, NorthStar Medical Radioisotopes (NMR), Orano Group, Viewpoint Molecular Targeting, RadioMedix, Telix Pharmaceuticals Limited., TerraPower, LLC, NIOWAVE Inc. and IONETIX Corporation. among others.

Recent Market Developments

• In January 2023, in a Phase 1 clinical trial, Orano Med, a pharmaceutical company, announced that they have given the initial 212Pb-GRPR dose. This therapy utilizes lead-212 and targets patients with solid tumors displaying the gastrin-releasing peptide receptor.
• In June 2022, Alpha Tau Medical Ltd., a company specializing in medical technology, has received approval from the U.S. Food and Drug Administration (FDA) for its Investigational Device Exemption (IDE) application. This approval grants them the ability to start an important study across multiple centers, focusing on the treatment of recurrent cutaneous Squamous Cell Carcinoma (SCC) using their Alpha DaRT technology.
• In November 2022, Actinium released favorable 1-Year and 2-Year overall survival results for individuals with relapsed or refractory Acute Myeloid Leukemia (AML) who participated in the Phase 1 Actimab-A CLAG-M combination trial.